The life sciences investment landscape in the UK and Nordics is experiencing a notable resurgence after a period of stagnation. According to HSBC Innovation Banking’s report on UK and Nordic Life Sciences Investment Trends for the first half of 2025, the sector is finding its momentum again. Deal volumes are on the rise, valuations are improving, and investors are increasingly focusing on fewer, but more significant opportunities, often referred to as “mega deals.”
To gain insights into this revitalization and its potential growth areas, Deep Dive engaged with Mike White, Head of Life Sciences and Healthcare at HSBC Innovation Banking. He offered his perspective on the key factors influencing investment in the UK and Nordics, the impact of artificial intelligence (AI), and the significance of the upcoming year for the industry.
Current Trends in Life Sciences Investment
The report indicates a dynamic industry landscape. Mike White observes that the UK and Nordic regions are reflecting trends seen in US life sciences venture funding, particularly a shift towards high-quality management teams, compelling scientific research, and innovative business models in health tech and med tech. Notably, UK investments surged by approximately 21% to £1.8 billion in the first half of 2025, largely due to mega deals in the $50-$100 million range. This influx of funding is crucial for companies aiming to sustain operations during a period of reduced IPO activity, as mergers and acquisitions (M&A) become the primary exit strategy.
However, this trend also brings challenges, as the number of life science companies in the UK and Nordics is gradually declining. While fewer firms are being funded, the focus is shifting towards those with robust prospects, which could undermine the ecosystem’s health if early-stage investments continue to dwindle.
Emerging Investment Areas
Investment activity is particularly vibrant in three sectors: medical devices, health tech, and oncology. The medical devices sector witnessed its strongest performance in three years during the first half of 2025, exemplified by OrganOx’s oversubscribed £108 million funding round, followed by a $1.5 billion acquisition by Terumo.
In health tech, significant funding rounds, such as Neko Health’s $260 million Series B, indicate strong investor confidence in European health tech innovation. Furthermore, early-stage health tech companies are seeing renewed interest, particularly in alternative care models.
On the biotech front, oncology remains a focal point, especially around antibody drug conjugates (ADCs). Although investment in this area cooled slightly as investors awaited critical milestones, the overall trajectory of oncology investment remains positive. Increased attention is also being directed toward neurodegenerative diseases and central nervous system conditions, spurred by major acquisitions and the potential of new therapies.
The Strength of UK Innovation
The UK’s reputation for exceptional research and development, particularly within the Golden Triangle of London, Cambridge, and Oxford, serves as a significant driver of early-stage innovation. The concentration of skilled researchers and institutions fosters a collaborative environment that accelerates the development of groundbreaking therapies.
While access to early-stage capital is strong, the UK faces challenges in scaling biotech ventures. The need for substantial funding to support late-stage trials often leads companies to seek capital in the US market, which can create a gap in the domestic ecosystem for mid-stage firms.
The Barbell Effect in Funding
The ‘barbell effect’ refers to the concentration of investment at both early and late stages, leaving mid-stage companies vulnerable. Investors tend to provide significant funding to early-stage firms with promising management teams and innovative approaches, allowing them to weather market uncertainties. However, this dynamic poses risks for mid-stage companies that may struggle to secure necessary funding to advance their development.
The Role of AI in Investment Trends
The rise of AI is reshaping the life sciences investment landscape. While some view the current AI boom as a potential bubble, its application in drug discovery is proving transformative. AI technologies are enabling researchers to identify previously difficult targets and accelerate the early stages of drug development.
The largest deal of the year, Isomorphic Labs, exemplifies this trend. Although not yet clinical, its pre-clinical work has the potential to revolutionize how drugs are developed, indicating a shift in focus toward harnessing AI in life sciences.
Looking Ahead
As we move toward the latter half of 2025, there are promising indicators for biotech, health tech, and med tech sectors. A robust IPO pipeline is emerging, suggesting that the market may soon unlock opportunities for public offerings. This momentum could invigorate early-stage funding and stabilize the landscape as uncertainty decreases and regulatory consistency improves.
In conclusion, the life sciences sector in the UK and Nordics is poised for transformation, driven by strategic investment trends and technological advancements. Although challenges remain, the combination of burgeoning sectors and innovative approaches sets the stage for a vibrant future in life sciences.
- Key Takeaways:
- The UK and Nordics are experiencing a revival in life sciences investment, with increased deal volumes and valuations.
- Significant funding is concentrated in medical devices, health tech, and oncology, highlighting investor confidence.
- The UK’s innovation ecosystem remains robust, but scaling challenges persist, particularly in securing late-stage funding.
- The barbell effect is evident, with funding concentrated at the extremes of the investment spectrum.
- AI is driving new investment opportunities, particularly in early-stage drug discovery and development.
Read more → pharmaphorum.com